anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: The literature on non-small cell lung cancer (NSCLC) brain metastases (BMs) managed using stereotactic radiosurgery (SRS) relies mainly on single-institution studies or randomized controlled trials (RCTs). There is a literature gap on clinical and radiological outcomes of SRS for NSCLC metastases in real-world practice. The objective of this study was to benchmark mortality and progression outcomes in patients undergoing SRS for NSCLC BMs and identify risk factors for these outcomes using a national quality registry.
METHODS: The SRS Registry of the NeuroPoint Alliance was used for this study. This registry included patients from 16 enrolling sites who underwent SRS from 2017 to 2022. Data are prospectively collected without a prespecified research purpose. The main outcomes of this analysis were overall survival (OS), out-of-field recurrence, local progression, and intracranial progression. All time-to-event investigations included Kaplan-Meier analyses and multivariable Cox regressions.
RESULTS: Two hundred sixty-four patients were identified, with a mean age of 66.7 years and a female proportion of 48.5%. Most patients (84.5%) had a Karnofsky Performance Status (KPS) score of 80-100, and the mean baseline EQ-5D score was 0.539 quality-adjusted life years. A single lesion was present in 53.4% of the patients, and 29.1% of patients had 3 or more lesions. The median OS was 28.1 months, and independent predictors of mortality included no control of primary tumor (hazard ratio [HR] 2.1), KPS of 80 (HR 2.4) or lower (HR 2.4), coronary artery disease (HR 2.8), and 5 or more lesions present at the time of SRS treatment (HR 2.3). The median out-of-field progression-free survival (PFS) was 24.8 months, and the median local PFS was unreached. Intralesional hemorrhage was an independent risk factor of local progression, with an HR of 6.0. The median intracranial PFS was 14.0 months and was predicted by the number of lesions at the time of SRS (3-4 lesions, HR 2.2; 5-14 lesions, HR 2.5).
CONCLUSIONS: In this real-world prospective study, the authors used a national quality registry and found favorable OS in patients with NSCLC BMs undergoing SRS compared with results from previously published RCTs. The intracranial PFS was mainly driven by the emergence of new lesions rather than local progression. A greater number of lesions at baseline was associated with out-of-field progression, while intralesional hemorrhage at baseline was associated with local progression.
The invention relates to a rose mallow active extract, a skin care compound, a preparation method and an application thereof and a skin care product. The main technical scheme adopted is as follows: an active extract of Rosa labra (Thunb.) DC contains ethyl gallate and phenethyl 6' -O-galloyl-beta-D-glucoside. Wherein, in the rose mallow active extract, the mass percentage of the ethyl gallate is not less than 0.325 percent, and the mass percentage of the phenethyl 6' -O-galloyl-beta-D-glucoside is not less than 0.25 percent. A skin care compound is ethyl gallate or phenethyl 6' -O-galloyl-beta-D-glucoside. The invention is mainly used for providing or preparing the rose mallow active extract and separating skin care compounds from the rose mallow active extract; wherein, the rose mallow active extract and the skin care compound can be used as DPPH free radical scavenger and tyrosinase inhibitor, and can be applied to the preparation of anti-aging and whitening skin care products.
The CG performed the traditional training while the EG carried out the CST. The training load was calculated to be 7-8 RPE in order that both groups (EG and CG) undergo an equivalent intensity and training load.
Severe complications like post-acute thrombosis, respiratory failure, and cardiac and vascular damage may increase the likelihood of future morbidity and mortality in recovered COVID-19 patients. Although the current rate of new COVID-19 infection has dropped, the risk of morbidity, mortality, and organ dysfunction among the survivors of COVID-19 infection is significant. An association between COVID-19 and an increased odds of acute kidney injury, renal replacement treatment, use of insulin, pulmonary embolism, stroke, myocarditis, arrhythmia, and increased troponin was found in US veterans admitted to hospital with COVID-19 versus a control group of patients with seasonal influenza. This comparative approach to examining post-acute sequelae in individuals who are hospitalized with COVID-19 versus individuals with seasonal influenza (using a high-dimensional approach and thorough examination of prespecified outcomes) suggests that there is a substantially higher burden of a broad array of post-acute sequelae in the individuals who are hospitalized with COVID-19, which provides features that differentiate post-acute COVID-19 (both in the magnitude of risk and the breadth of organ involvement) from a post-influenza viral syndrome.

Given the prevalence rates, it is evident that individuals in the post-acute phase even 12-months after their initial diagnosis continue to have abnormal physiological characteristics and increased utilization of healthcare resources as a consequence of altered health. This forces the conclusion that COVID-19 needs to be treated as a 'chronic condition' exhibiting an increased risk of morbidity, use of healthcare resources as well as a substantial burden of health loss that spans across pulmonary and extrapulmonary organ systems. From evidence and reasoning, it would be appropriate to infer that the next wave related to COVID-19 may not necessarily be a new strain but rather the surge of hospitalizations due to post-acute complications. Therefore, developing holistic and multidisciplinary long-term care strategies for patients with COVID-19 is emerging as an unmet need. To address these knowledge gaps, this study aims to recruit 'severe COVID-19' cases (i.e. those who required hospitalization during the acute COVID-19 phase), who have increased rates of multiorgan failure compared with the expected risk in the general population, to characterize the changes in cardiorespiratory parameters leading up to a decompensation event. Early prediction, real-time risk triaging shall be invaluable for better clinical decision making, preventing complications, controlling disease progression and improving outcomes.
Rats treated with nicardipine in the diet (at concentrations calculated to provide daily dosage levels of 5, 15 or 45 mg/kg/day) for 2 years showed a dose dependent increase in thyroid hyperplasia and neoplasia (follicular adenoma/carcinoma). One and 3 month studies in the rat have suggested that these results are linked to a nicardipine-induced reduction in plasma thyroxine (T4) levels with a consequent increase in plasma levels of thyroid stimulating hormone (TSH). Chronic elevation of TSH is known to cause hyperstimulation of the thyroid. In rats on an iodine deficient diet, nicardipine administration for one month was associated with thyroid hyperplasia that was prevented by T4 supplementation. Mice treated with nicardipine in the diet (at concentrations calculated to provide daily dosage levels of up to 100 mg/kg/day) for up to 18 months showed no evidence of neoplasia of any tissue and no evidence of thyroid changes. There was no evidence of thyroid pathology in dogs treated with up to 25 mg nicardipine/kg/day for one year and no evidence of effects of nicardipine on thyroid function (plasma T4 and TSH) in man.

There was no evidence of a mutagenic potential of nicardipine in a battery of genotoxicity tests conducted on microbial indicator organisms, in micronucleus tests in mice and hamsters, or in a sister chromatid exchange study in hamsters.

No impairment of fertility was seen in male or female rats administered nicardipine at oral doses as high as 100 mg/kg/day (50 times the 40 mg TID maximum recommended antianginal or antihypertensive dose in man, assuming a patient weight of 60 kg).
PROBLEM TO BE SOLVED: To efficiently obtain the subject derivative by ethyl acetate treatment followed by active carbon treatment. SOLUTION: This colorless and odorless glucopyranoside derivative is obtained by purifying the corresponding glucopyranoside derivative through conducting an ethyl acetate treatment followed by active carbon (10-500 mesh) treatment. The amount of the ethyl acetate to be used is e.g. about 0.5-10 (pref. about 1-3) pts.wt. per pt.wt. of the crude glucopyranoside derivative. The active carbon to be used may be such active carbon derived from e.g. wood, coconut husks and readily available in the market.
In a controlled pharmacokinetic study, 5 of 13 subjects experienced reversible suppression of the adrenals at any time during the 14 days of Olux Foam therapy to at least 20% of the body surface area. Of the 13 subjects studied, 1 of 9 with psoriasis were suppressed after 14 days and all 4 of the subjects with atopic dermatitis had abnormal cortisol levels indicative of adrenal suppression at some time after starting therapy with Olux Foam. (See Table 3 below.)

Systemic absorption of topical corticosteroids has produced reversible adrenal suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients (see PRECAUTIONS).

In a controlled clinical trial (188 subjects) with Olux Foam in subjects with psoriasis of the scalp, there were no localized scalp adverse reactions reported in the Olux Foam treated subjects. In two controlled clinical trials (360 subjects) with Olux Foam in subjects with psoriasis of non-scalp regions, localized adverse events that occurred in the Olux Foam treated subjects included application site burning (10%), application site dryness (< 1%), and other application site reactions (4%).

In larger controlled trials with other clobetasol propionate formulations, the most frequently reported local adverse reactions have included burning, stinging, irritation, pruritus, erythema, folliculitis, cracking and fissuring of the skin, numbness of the fingers, skin atrophy, and telangiectasia (all less than 2%).

The following additional local adverse reactions have been reported with topical corticosteroids, but they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids such as Olux Foam. These reactions are listed in an approximate decreasing order of occurrence: dryness, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, and miliaria.
The present invention provides methods of inhibiting replication of cold-causing viruses in respiratory epithelium cells and elaboration of IL-8 in the cells of subjects exposed to the viruses, by interfering with the virus binding to the cell membrane receptor that stimulates elaboration of IL-8 and viral replication. A polypeptide that binds to a virus and interferes with the binding of the virus to the cell is provided. An antibody that binds to a cell membrane-bound cytochrome and interferes with the virus binding to the cytochrome is also provided. Further, a chemical inhibitor of a membrane-bound cytochrome, that inhibitis viral replication in and elaboration of IL-8 by the cell, is provided. Moreover, the present invention provides methods of treating and reducing cold symptoms in a subject comprising administering to a subject any of the compositions of this invention. Further, the invention provides methods of screening for a compound which inhibits the interaction of a cold-causing virus and a respiratory epithelium cell.
Harsh parenting is associated with serious and costly mental health problems among youth, including substance use, mood disorders, and suicidal ideation and behaviors. Of concern, these parenting practices are most common among families from impoverished communities; however, many behaviorally-based parenting interventions do not take into account the unique mechanisms linking environmental disadvantage to parenting approaches. While the causes of harsh parenting are complex and varied, one such mechanism may be parents' tendencies to prioritize immediate rewards (such as stopping a child's misbehavior via physical punishment like spanking and hitting) relative to larger, but delayed rewards (including improved parent-child relationship quality), known as delay discounting.

The aims of the current study are to conduct a Stage 1 parent-child dyad randomized control trial (RCT) (n = 72) examining the effectiveness of a brief, episodic future thinking (EFT) intervention in a community setting serving low-income mothers and additional implementation data. Participants will be randomized to receive either Episodic Future Thinking (EFT) or Episodic Recent Thinking (ERT) intervention arms. This case series will examine the efficacy of episodic future thinking (EFT) compared to episodic recent thinking (ERT) to target reduction of parenting-related delay discounting. Outcomes will evaluate the effect of EFT on reducing maternal delay discounting and harsh parenting and improving child clinical outcomes.
Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), NLX-ER (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To describe the effects of repeated-dose naloxone in preventing loperamide-induced delay of WGT, OCT and CTT and measure pharmacokinetics of naloxone.
The invention relates to a traditional Chinese medicine wine formula for treating male oligospermia. The traditional Chinese medicine wine is prepared from, by weight, 200 g of fructus lycii, 200 g of semen cuscutae, 200 g of semen plantaginis, 200 g of Chinese magnolcavine fruit, 200 g of semen allii tuberosi, 200 g of fructus ligustri lucidi, 200 g of euphoria longan(Lour.)Steud., 500 g of cherokee rose fruit, 200 g of processed radix aconiti lateralis, 200 g of rubus idaeus and 2500 g of baijiu with the degree of 55 percent. The ten traditional Chinese medicines are mashed and put into a container, 2500 g of baijiu is added, sealed soaking is conducted for 10-15 d, residue filtering is conducted, and bottling is conducted for use; the traditional Chinese medicine wine is orally administered for 10-20 g each time and 2-3 times each day. The traditional Chinese medicine wine prepared through the formula has the effects of tonifying Yin and Yang and biochemistry of kidney essence, and good treatment effects on treating idiopathic oligospermia, congenitally deficient or postnatally disordered oligospermia, mental fatigue, dizziness and tinnitus, soreness of the waist, chest distress, abdominal distension or the like are achieved. The traditional Chinese medicine wine formula for treating the male oligospermia has the advantages of being low in treatment cost, convenient, high in cure rate, free of side effect and the like.
GRT0151Y will be administered to participants as 50 mg capsules in a dose escalation range of 150, 200, 250, 300, 350 and 400 mg. Dose levels were increased by increments of 50 mg to a maximum of 400 mg, only after the previous dose level was found to be well-tolerated. During each treatment period, participants randomly received either GRT0151Y or matching placebo, in a manner that no participant received placebo in two consecutive periods.
Topical formulations of lidocaine may be absorbed to a greater extent through mucous membranes and abraded, fissured or irritated skin than through intact skin. Product should not be ingested or applied into the mouth, inside of the nose or in the eyes. Product should not be used in the ears. Any situation where lidocaine penetrates beyond the tympanic membrane into the middle ear is contraindicated because of ototoxicity associated with lidocaine observed in animals when instilled in the middle ear. Product should not come into contact with the eye or be applied into the eye because of the risk of severe eye irritation and the loss of eye surface sensation, which reduces protective reflexes and can lead to corneal irritation and possibly abrasion. If eye contact occurs, rinse out the eye immediately with saline or water and protect the eye surface until sensation is restored.
Continuous stimulation of tumor neoantigens and various cytokines in the tumor microenvironment leads to T cell dysfunction, but the specific mechanisms by which these key factors are distributed among different cell subpopulations and how they affect patient outcomes and treatment response are incompletely characterized. By integrating single-cell and bulk sequencing data of non-small cell lung cancer patients, we constructed a clinical outcome-associated T cell exhaustion signature. We discovered a significant association between the T cell exhaustion state and tumor cell hypoxia. Hypoxic malignant cells were significantly correlated with the proportion of exhausted T cells, and they co-occurred in patients at advanced stage. By analyzing the ligand-receptor interactions between these two cell states, we observed that T cells were recruited towards tumor cells through production of chemokines such as CXCL16-CXCR6 axis and CCL3/CCL4/CCL5-CCR5 axis. Based on 15 immune checkpoint blockade (ICB)-treatment cohorts, we constructed an interaction signature that can be used to predict the response to immune checkpoint blockade therapy. Among genes composed of the signature, CXCR6 alone has similarly high prediction efficacy (Area Under Curve (AUC) = 1, 0.89 and 0.73 for GSE126044, GSE135222 and GSE93157, respectively) with the signature and thus could serve as a potential biomarker for predicting immunotherapy response. Together, we have discovered and validated a significant association between exhausted T cells and hypoxic malignant cells, elucidating key interaction factors that significantly associated with response to immunotherapy.
BACKGROUND: Renal hypoxia and ischemia significantly contribute to chronic kidney disease (CKD) progression, underscoring the need for noninvasive quantitative assessments. This study employs blood oxygenation level-dependent magnetic resonance imaging (BOLD-MRI) and arterial spin labeling (ASL) MRI to comprehensively evaluate renal oxygenation and blood flow in CKD patients.
METHODS: Forty-two CKD patients across stages 1-5 and ten healthy volunteers underwent simultaneous BOLD-MRI and ASL-MRI. We measured oxygenation (T2* values) and renal blood flow (RBF) in both the renal cortex and medulla, assessing their correlations with estimated glomerular filtration rate (eGFR) and other renal function indicators.
RESULTS: BOLD and ASL revealed higher oxygenation and RBF in the renal cortex than in the medulla. Across CKD stages 2-5, both cortical and medullary oxygenation levels, as well as RBF, were lower than those in the control group and progressively decreased with CKD advancement. Additionally, renal oxygenation and blood flow levels positively correlated with serum creatinine (SCr), cystatin C (Cys C), and blood urea nitrogen (BUN), and negatively correlated with estimated glomerular filtration rate (eGFR) (p < 0.001). However, no significant correlation was observed with uric acid (UA) (p > 0.05). Notably, patients with CKD stages 1-3 exhibited strong correlations between renal oxygenation levels, RBF, and eGFR, while those with CKD stages 4-5 displayed weak correlations.
CONCLUSION: BOLD-MRI and ASL-MRI effectively measure renal oxygenation and perfusion noninvasively, confirming their utility in tracking CKD progression. These modalities provide accurate assessments of renal function and hypoxic-ischemic injuries across CKD stages, particularly in the early stages.
BACKGROUND: This study aimed to evaluate the efficiency of noninvasive prenatal screening (NIPS) technology in screening for microdeletions in the 7q11.23 region.
METHODS: 19,607 pregnant women underwent NIPS in our hospital. Maternal peripheral cell-free foetal DNA (cffDNA) was routinely screened for aneuploidy by cffDNA enrichment and simultaneously analyzed for pathogenic copy number variants (CNVs). The Williams syndrome (WS) 7q11.23 region was targeted in this study. Chromosomal microarray analysis (CMA) was used to verify the screen-positive samples.
RESULTS: The mean concentration of cffDNA before and after enrichment increased from 9.44% to 19.32%, with a statistically significant difference. Two out of 19,607 samples tested for CNVs were found to have a heterozygous deletion at the 7q11.23 region, indicating a high risk for WS. CMA results confirmed the 1.5 megabase (Mb) deletions at the 7q11.23 region in amniotic fluid samples. One of the two WS foetuses had a small left ventricle by ultrasound screening, and the other did not have a significant cardiovascular abnormality phenotype.
CONCLUSIONS: NIPS screening for Williams syndrome can be achieved by enriching cell-free foetal DNA and improving bioinformatic analysis algorithms.
NEW MATERIAL:A compound of the formula (R is H, acetyl). USE:Anti-viral-hepatitic or the like. PREPARATION:A plant, Swertia mileensis, is dried, and the foliage parts are crushed and extracted with ethanol. The extract, after evaporation of the solvent, treated with benzene. The benzene-insoluble fraction including water-soluble components is fractionated with ethyl acetate and water, and the fraction soluble in ethyl acetate is treated with silica-gel chromatography. Finally, the collected active fraction is purified repetitively by column chromatography using silica gel and Sephadex to isolate the subject substance.
PURPOSE:To provide an antihyperlipemic agent having low toxicity and excellent antihyperlipemic activity, by using a specific 3,5-di-tert-butylbenzene derivative or its salt as an active component. CONSTITUTION:The objective antihyperlipemic agent is produced by using the 3,5-di-tert-butylbenzene derivative of formula I {R<1> is H, lower alkyl, etc.; R<2> is group of formula II, formula III [R<4> is H or -COR<5> (R<5> is H or lower alkyl)], etc.} or its salt as active component. A concrete example of the compound of formula I is alpha-(3,5-di-tert-butyl-4-hydroxybenzylidene)-gamma-butyrolactone. The administration of the compound of formula I is also effective to lower the arteriosclerotic index and improve the lipid metabolism. Moreover the compound has low toxicity. Dose: preferably 20mg-5g per day. A compound of furmula  I wherein R<2> is group of formula II can be prepared by reacting the aldehyde of formula IV with the compound of formula V (Ar is aryl).
General: Recommended dosages of digoxin may require considerable modification because of individual sensitivity of the patient to the drug, the presence of associated conditions, or the use of concurrent medications. In selecting a dose of digoxin, the following factors must be considered:

  1. The body weight of the patient. Doses should be calculated based upon lean (i.e., ideal) body weight.
  2. The patient's renal function, preferably evaluated on the basis of estimated creatinine clearance.
  3. The patient's age. Infants and children require different doses of digoxin than adults. Also, advanced age may be indicative of diminished renal function even in patients with normal serum creatinine concentration (i.e., below 1.5 mg/dL).
  4. Concomitant disease states, concurrent medications, or other factors likely to alter the pharmacokinetic or pharma-codynamic profile of digoxin (see PRECAUTIONS).
Prepn. of implants (I) consisting of a solid esp. metallic nucleus with a tissue-compatible coating, in which the surface of the nucleus is initially roughened, thermally treated at a suitable temperature to form an oxide layer and then coated with a layer of hydroxyapatite. - Also claimed is (I) in which the metallic nucleus consists of a light metal (alloy) or steel (alloy). - Synthetic or natural hydroxylapatite esp. from algae is used and is applied by plasma spraying. The thickness of the coating is 0.05-0.15 mm and has a porosity of 7-10%. The surface is roughened by sand-blasting and has a roughness of 3-8 micron.